Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial
- PMID: 28011612
- DOI: 10.1093/cid/ciw731
Oral Vancomycin Followed by Fecal Transplantation Versus Tapering Oral Vancomycin Treatment for Recurrent Clostridium difficile Infection: An Open-Label, Randomized Controlled Trial
Abstract
Background: Fecal transplantation (FT) is a promising treatment for recurrent Clostridium difficile infection (CDI), but its true effectiveness remains unknown. We compared 14 days of oral vancomycin followed by a single FT by enema with oral vancomycin taper (standard of care) in adult patients experiencing acute recurrence of CDI.
Methods: In a phase 2/3, single-center, open-label trial, participants from Ontario, Canada, experiencing recurrence of CDI were randomly assigned in a 1:1 ratio to 14 days of oral vancomycin treatment followed by a single 500-mL FT by enema, or a 6-week taper of oral vancomycin. Patients with significant immunocompromise, history of fulminant CDI, or irreversible bleeding disorders were excluded. The primary endpoint was CDI recurrence within 120 days. Microbiota analysis was performed on fecal filtrate from donors and stool samples from FT recipients, as available.
Results: The study was terminated at the interim analysis after randomizing 30 patients. Nine of 16 (56.2%) patients who received FT and 5 of 12 (41.7%) in the vancomycin taper group experienced recurrence of CDI, corresponding with symptom resolution in 43.8% and 58.3%, respectively. Fecal microbiota analysis of 3 successful FT recipients demonstrated increased diversity. A futility analysis did not support continuing the study. Adverse events were similar in both groups and uncommon.
Conclusions: In patients experiencing an acute episode of recurrent CDI, a single FT by enema was not significantly different from oral vancomycin taper in reducing recurrent CDI. Further research is needed to explore optimal donor selection, FT preparation, route, timing, and number of administrations.
Clinical trials registration: NCT01226992.
Keywords: fecal transplantation; intestinal microbiota; randomized controlled trial.; recurrent Clostridium difficile infection; vancomycin taper.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
Comment in
-
Fecal Fixation: Fecal Microbiota Transplantation for Clostridium difficile Infection.Clin Infect Dis. 2017 Feb 1;64(3):272-274. doi: 10.1093/cid/ciw735. Epub 2016 Nov 9. Clin Infect Dis. 2017. PMID: 28011611 No abstract available.
-
Fecal Microbiota Transplantation: Do We Need Harmonization?Clin Infect Dis. 2017 May 1;64(9):1292. doi: 10.1093/cid/cix092. Clin Infect Dis. 2017. PMID: 28158478 No abstract available.
-
Reply to Galperine et al and Jansen.Clin Infect Dis. 2017 May 1;64(9):1293-1295. doi: 10.1093/cid/cix094. Clin Infect Dis. 2017. PMID: 28158498 No abstract available.
-
Fecal Microbiota Transplant vs Oral Vancomycin Taper: Important Undiscussed Limitations.Clin Infect Dis. 2017 May 1;64(9):1292-1293. doi: 10.1093/cid/cix093. Clin Infect Dis. 2017. PMID: 28158664 No abstract available.
Similar articles
-
Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.Transpl Infect Dis. 2016 Aug;18(4):628-33. doi: 10.1111/tid.12550. Epub 2016 Jul 5. Transpl Infect Dis. 2016. PMID: 27214585 Clinical Trial.
-
Economic evaluation of fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection in Australia.J Gastroenterol Hepatol. 2016 Dec;31(12):1927-1932. doi: 10.1111/jgh.13402. J Gastroenterol Hepatol. 2016. PMID: 27043242
-
Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.JAMA. 2014 Nov 5;312(17):1772-8. doi: 10.1001/jama.2014.13875. JAMA. 2014. PMID: 25322359 Clinical Trial.
-
Fecal Microbiota Therapy for Clostridium difficile Infection: A Health Technology Assessment.Ont Health Technol Assess Ser. 2016 Jul 1;16(17):1-69. eCollection 2016. Ont Health Technol Assess Ser. 2016. PMID: 27516814 Free PMC article. Review.
-
Treatment of recurrent and severe Clostridium difficile infection.Annu Rev Med. 2015;66:373-86. doi: 10.1146/annurev-med-070813-114317. Annu Rev Med. 2015. PMID: 25587656 Review.
Cited by
-
Comparative effectiveness of treatments for recurrent Clostridioides difficile infection: a network meta-analysis of randomized controlled trials.Front Pharmacol. 2024 Oct 17;15:1430724. doi: 10.3389/fphar.2024.1430724. eCollection 2024. Front Pharmacol. 2024. PMID: 39484168 Free PMC article.
-
Faecal microbiota transplantation for refractory C lostridium difficile infection.BMJ Case Rep. 2019 Nov 27;12(11):e231027. doi: 10.1136/bcr-2019-231027. BMJ Case Rep. 2019. PMID: 31780599 Free PMC article.
-
Adverse events in fecal microbiota transplantation: a systematic review and meta-analysis.Ann Gastroenterol. 2022 Mar-Apr;35(2):150-163. doi: 10.20524/aog.2022.0695. Epub 2022 Feb 14. Ann Gastroenterol. 2022. PMID: 35479587 Free PMC article.
-
Capsules for Fecal Microbiota Transplantation in Recurrent Clostridium difficile Infection: The New Way Forward or a Tough Pill to Swallow?JAMA. 2017 Nov 28;318(20):1979-1980. doi: 10.1001/jama.2017.17969. JAMA. 2017. PMID: 29183052 Free PMC article. No abstract available.
-
Health economic evaluations comparing faecal microbiota transplantation with antibiotics for treatment of recurrent Clostridioides difficile infection: a systematic review.Health Econ Rev. 2021 Jan 13;11(1):3. doi: 10.1186/s13561-021-00301-7. Health Econ Rev. 2021. PMID: 33439367 Free PMC article. Review.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical